Par Pharmaceutical Companies

Activities: Manufacturing Pharmaceutical

Trending Articles

  1. LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
  2. Fasenra for EGPA: addressing unmet needs Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
  3. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  4. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
  5. Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

Related Content

Finance

Endo to purchase Par Pharmaceutical for US$8.05bn

Expanding generics business, product portfolio, pipeline and manufacturing capabilities
Manufacturing

Par Pharmaceutical to buy JHP Pharmaceuticals

Adds sterile injectable products to its portfolio
Finance

Par Pharmaceutical agrees to be acquired by private equity

US generics firm will continue to seek other buyers
Pharmaceutical

Par Pharmaceutical makes two promotions

To manage the expanded company and its subsidiaries
Finance

Par Pharmaceutical completes acquisition of Anchen

Purchase brings five commercialised products and 27 ANDAs on file with the US FDA
Finance

Par Pharmaceutical to pay US$410m for Anchen

Second acquisition of a privately held generics manufacturer this year
Finance

Par Pharmaceutical to acquire Edict Pharmaceuticals in India

Strengthens r&d and adds manufacturing capacity
Subscribe now